Abstract: There is provided a drug which exhibits preventive and therapeutic effects on virus infectious diseases by inhibiting virus-derived protease on the basis of various physiological activity actions of an active sulfur compound(s) which exists in living organisms.

Abstract: The present invention is a biomarker for diagnosing infectious disease wherein the biomarker is a sulfur metabolite, and the sulfur metabolite may be a sulfur metabolite present in exhaled air, and the sulfur metabolite can be detected from exhaled air condensate. The biomarker for infectious disease includes a biomarker for diagnosing bacterial and viral infection, especially new coronavirus infection; a biomarker for diagnosing pneumonias such as infectious pneumonia, especially interstitial pneumonia due to new coronavirus infection, and additionally alveolar pneumonia; and a biomarker for diagnosing exacerbation due to infection, especially for diagnosing the risk of the transition to exacerbation due to new coronavirus infection. The present invention is further a diagnostic system for detecting a biomarker for diagnosing infection comprising a sulfur metabolite from exhaled air, and is a system for determining infection, especially for diagnosing new coronavirus infection.

Abstract: A method of synthesize cysteine hydropersulfide (CysSSH) includes taking a substrate L-cysteine, and performing a reaction catalyzed by cysteinyl-tRNA synthetases (CARSs).

Abstract: Provided is a quantitative determination method for sulfur compounds in a target group selected from a plurality of groups, e.g., a group including cysteine and related reactive sulfurs, including the steps of: performing an LC/MS/MS measurement of a standard substance having a known concentration of a base compound, e.g.

Abstract: A method of synthesize cysteine hydropersulfide (CysSSH) includes taking a substrate L-cysteine, and performing a reaction catalyzed by cysteinyl-tRNA synthetases (CARSs).

Abstract: Method of using sulfide: quinone oxidoreductase (SQR) for persulfide-mediated generation of mitochondrial membrane potential and energy production, and method of using SQR for catalyzing proton and electron transfer from hydropersulfides to a mitochondrial electron transport chain.

Abstract: A method of synthesize cysteine hydropersulfide (CysSSH) includes taking a substrate L-cysteine, and performing a reaction catalyzed by cysteinyl-tRNA synthetases (CARSs).

Abstract: A method of synthesize cysteine hydropersulfide (CysSSH) includes taking a substrate L-cysteine, and performing a reaction catalyzed by cysteinyl-tRNA synthetases (CARSs).

Abstract: The present invention addresses the problem of providing an intraocular irrigating solution that allows the intraocular tissue to be sufficiently protected during ophthalmic surgery and further has high safety. The problem is solved by an intraocular irrigating solution containing at least one of active sulfur molecules of which examples include cysteine persulfide and glutathione persulfide.

Abstract: The present invention addresses the problem of providing an intraocular irrigating solution that allows the intraocular tissue to be sufficiently protected during ophthalmic surgery and further has high safety. The problem is solved by an intraocular irrigating solution containing at least one of active sulfur molecules of which examples include cysteine persulfide and glutathione persulfide.

Abstract: An object of the present invention is to provide a novel compound that is an agonist of guanosine-3?,5?-cyclic monophosphate and has an effect of activating protein kinase G. The present invention provides 8-guanosine-3?,5?-cyclic monophosphate compound which is represented by the following formula, and a pharmaceutical composition, especially a protein kinase G activating agent, which contains the 8-guanosine-3?,5?-cyclic monophosphate compound as an active ingredient.

Abstract: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.

Abstract: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.

Abstract: An object of the present invention is to provide a novel compound that is an agonist of guanosine-3?,5?-cyclic monophosphate and has an effect of activating protein kinase G. The present invention provides 8-guanosine-3?,5?-cyclic monophosphate compound which is represented by the following formula, and a pharmaceutical composition, especially a protein kinase G activating agent, which contains the 8-guanosine-3?,5?-cyclic monophosphate compound as an active ingredient.

Abstract: An antitumor agent, which is a combination of an oxidoreductase, such as xanthine oxidase chemically conjugated to a polymer such as poly ethylene glycol, for initial administration and accumulation in the tumor tissue followed by administration and of a substrate for the oxidoreductase which releases reactive oxygen species. Improved tumor selective cytotoxic activity results.

Abstract: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.

Abstract: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.

Abstract: The present invention provides a nitrosylated albumin variant wherein one or more amino acid residues of constituent amino acid sequences are substituted, or a different amino acid residue is inserted into a part of the constituent amino acid sequences. The albumin variant has sufficient antimicrobial property and permits application as various useful pharmaceutical compositions.

Abstract: An antitumor agent, which is a combination of an oxidoreductase, such as xanthine oxidase chemically conjugated to a polymer such as poly ethylene glycol, for initial administration and accumulation in the tumor tissue followed by administration and of a substrate for the oxidoreductase which releases reactive oxygen species. Improved tumor selective cytotoxic activity results.

Abstract: The present invention provides a nitrosylated albumin variant wherein one or more amino acid residues of constituent amino acid sequences are substituted, or a different amino acid residue is inserted into a part of the constituent amino acid sequences. The albumin variant has sufficient antimicrobial property and permits application as various useful pharmaceutical compositions.